549 related articles for article (PubMed ID: 23318279)
1. Pharmacokinetics of meropenem in critically ill patients with severe infections.
Binder L; Schwörer H; Hoppe S; Streit F; Neumann S; Beckmann A; Wachter R; Oellerich M; Walson PD
Ther Drug Monit; 2013 Feb; 35(1):63-70. PubMed ID: 23318279
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia.
Ariano RE; Nyhlén A; Donnelly JP; Sitar DS; Harding GK; Zelenitsky SA
Ann Pharmacother; 2005 Jan; 39(1):32-8. PubMed ID: 15598967
[TBL] [Abstract][Full Text] [Related]
3. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.
Roberts DM; Roberts JA; Roberts MS; Liu X; Nair P; Cole L; Lipman J; Bellomo R;
Crit Care Med; 2012 May; 40(5):1523-8. PubMed ID: 22511133
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients.
Mattioli F; Fucile C; Del Bono V; Marini V; Parisini A; Molin A; Zuccoli ML; Milano G; Danesi R; Marchese A; Polillo M; Viscoli C; Pelosi P; Martelli A; Di Paolo A
Eur J Clin Pharmacol; 2016 Jul; 72(7):839-48. PubMed ID: 27048201
[TBL] [Abstract][Full Text] [Related]
5. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.
Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C
Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601
[TBL] [Abstract][Full Text] [Related]
6. Meropenem removal in critically ill patients undergoing sustained low-efficiency dialysis (SLED).
Deshpande P; Chen J; Gofran A; Murea M; Golestaneh L
Nephrol Dial Transplant; 2010 Aug; 25(8):2632-6. PubMed ID: 20181801
[TBL] [Abstract][Full Text] [Related]
7. The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*.
Jamal JA; Udy AA; Lipman J; Roberts JA
Crit Care Med; 2014 Jul; 42(7):1640-50. PubMed ID: 24674926
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of short versus extended infusion meropenem dosing in critically ill patients: a pilot study.
Langan KM; Jacob J; Li J; Nation RL; Bellomo R; Howden B; Johnson PD
Crit Care Resusc; 2014 Sep; 16(3):190-6. PubMed ID: 25161021
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration.
Jamal JA; Mat-Nor MB; Mohamad-Nor FS; Udy AA; Wallis SC; Lipman J; Roberts JA
Int J Antimicrob Agents; 2015 Jan; 45(1):41-5. PubMed ID: 25455853
[TBL] [Abstract][Full Text] [Related]
10. Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis.
Tsai D; Stewart P; Goud R; Gourley S; Hewagama S; Krishnaswamy S; Wallis SC; Lipman J; Roberts JA
Int J Antimicrob Agents; 2016 Nov; 48(5):542-546. PubMed ID: 27771187
[TBL] [Abstract][Full Text] [Related]
11. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
[TBL] [Abstract][Full Text] [Related]
12. What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?
Alobaid AS; Brinkmann A; Frey OR; Roehr AC; Luque S; Grau S; Wong G; Abdul-Aziz MH; Roberts MS; Lipman J; Roberts JA
J Antimicrob Chemother; 2016 Mar; 71(3):696-702. PubMed ID: 26702922
[TBL] [Abstract][Full Text] [Related]
13. Decreased meropenem levels in Intensive Care Unit patients with augmented renal clearance: benefit of therapeutic drug monitoring.
Tröger U; Drust A; Martens-Lobenhoffer J; Tanev I; Braun-Dullaeus RC; Bode-Böger SM
Int J Antimicrob Agents; 2012 Oct; 40(4):370-2. PubMed ID: 22795654
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of meropenem and piperacillin in critically ill patients with indwelling surgical drains.
Adnan S; Li JX; Wallis SC; Rudd M; Jarrett P; Paterson DL; Lipman J; Udy AA; Roberts JA
Int J Antimicrob Agents; 2013 Jul; 42(1):90-3. PubMed ID: 23590897
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration.
Tegeder I; Neumann F; Bremer F; Brune K; Lötsch J; Geisslinger G
Clin Pharmacol Ther; 1999 Jan; 65(1):50-7. PubMed ID: 9951430
[TBL] [Abstract][Full Text] [Related]
16. The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study.
Shekar K; Fraser JF; Taccone FS; Welch S; Wallis SC; Mullany DV; Lipman J; Roberts JA;
Crit Care; 2014 Dec; 18(6):565. PubMed ID: 25636084
[TBL] [Abstract][Full Text] [Related]
17. Serum β-lactam concentrations in critically ill patients with cirrhosis: a matched case-control study.
Lheureux O; Trepo E; Hites M; Cotton F; Wolff F; Surin R; Creteur J; Vincent JL; Gustot T; Jacobs F; Taccone FS
Liver Int; 2016 Jul; 36(7):1002-10. PubMed ID: 26645828
[TBL] [Abstract][Full Text] [Related]
18. Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients.
Goncalves-Pereira J; Silva NE; Mateus A; Pinho C; Povoa P
BMC Pharmacol Toxicol; 2014 Apr; 15():21. PubMed ID: 24731745
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of continuous-infusion meropenem in a pediatric patient receiving extracorporeal life support.
Cies JJ; Moore WS; Dickerman MJ; Small C; Carella D; Chopra A; Parker J
Pharmacotherapy; 2014 Oct; 34(10):e175-9. PubMed ID: 25146254
[TBL] [Abstract][Full Text] [Related]
20. Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy?
Varghese JM; Jarrett P; Wallis SC; Boots RJ; Kirkpatrick CM; Lipman J; Roberts JA
J Antimicrob Chemother; 2015 Feb; 70(2):528-33. PubMed ID: 25336163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
